Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

This book will focus on recently developed targeted therapies other than monoclonal antibodies used in lymphoma patients, both in routine practice and investigative trials Divided by groups of drugs, the book will revisit the most relevant aspects of these targeted therapies with special emphasis on molecular mechanisms and clinical effects of resistance The book features a diverse array of internationally recognized experts